Executive Summary
Deep Generative Models for the Discovery of Antiviral Peptides Targeting Dengue Virus by Y Lee·2024·Cited by 1—Two peptides, 3a 3/20 and DS-05, showed superior therapeutic efficacy against DENV and were further evaluated in treating DHF/DSS induced by
The dengue virus poses a significant global health threat, with millions of infections occurring annually. Despite the widespread impact of dengue, there remains a critical need for effective therapeutic interventions. Traditional approaches, including vaccines like Dengvaxia, have shown varying efficacy, particularly in real-world settings against all four DENV serotypes. This has spurred intensive research into novel therapeutic strategies, with peptides emerging as a particularly promising avenue. The exploration of peptides as therapeutic agents for dengue virus is gaining momentum, driven by their unique advantages and the potential to overcome limitations of existing treatments.
Peptide-based therapies offer several compelling benefits over traditional pharmaceuticals or larger biological molecules like antibodies. Their small size allows for enhanced tissue penetration and a potentially broader range of targets within the dengue virus lifecycle. Furthermore, peptide drugs can be synthesized with high specificity, enabling precise targeting of viral components or host cell mechanisms crucial for viral replication. This precision can lead to reduced off-target effects and improved safety profiles. The design of peptide drugs is also highly adaptable, allowing for modifications to enhance stability, bioavailability, and efficacy, making them versatile tools in the fight against dengue.
Research into peptides for dengue virus treatment focuses on several key strategies that may help to overcome dengue infection. One prominent approach involves developing peptides that interfere with the viral replication cycle. These peptides can act at various stages, from inhibiting the entry of the virus into host cells to disrupting the assembly of new viral particles. For instance, studies have investigated peptides that target viral structural proteins or non-structural proteins (NS proteins). Specifically, peptides targeting DENV NS1 have shown significant promise. The DENV NS1 protein is crucial for viral replication and pathogenesis, and its inhibition via peptides represents an alternative antiviral therapeutic approach. Similarly, peptides designed to disrupt NS protein function can effectively impair viral genome replication and assembly, offering a robust strategy to combat DENV.
Another area of active research involves the design antiviral peptides targeting the dengue virus NS3 protease. The NS3 protease is essential for processing the viral polyprotein, making it a critical target for antiviral intervention. Advanced computational methods, including AI-driven pipelines and Deep Generative Models for the Discovery of Antiviral Peptides Targeting Dengue Virus, are being employed to identify and design novel peptides with high affinity for these targets. These in silico approaches accelerate the discovery process, allowing for the rapid screening of vast libraries of potential peptide candidates.
Furthermore, novel Peptides Derived from Dengue Virus Capsid Protein are being explored for their potential to translocate across biological barriers, such as the blood-brain barrier, through receptor-free mechanisms. This opens up possibilities for treating neurological complications associated with dengue.
The efficacy of peptides in combating dengue virus has been demonstrated through various studies. For example, the DET4 peptide has shown the ability to inhibit DENV-2 after its entry into target cells, as evidenced by the quantification of intracellular viral RNA load. Other research has identified inhibitory peptides with a half maximal inhibition concentration (IC50) in the micromolar range, indicating potent antiviral activity. The di-peptide, EF, for instance, was found to be highly effective in inhibiting DENV2 infection in vitro. Peptides targeting viral entry have also shown promise, with some demonstrating the ability to specifically block viral fusion with an IC50 in the 10 µM range.
Beyond directly targeting the virus, peptides are also being investigated for their immunotherapeutic potential. Peptide-ligand conjugate based immunotherapeutic approaches aim to mediate the immune elimination of soluble NS1 and DENV-infected host cells by leveraging pre-existing vaccine-induced immunity.
The development of peptides for dengue virus is not limited to synthetic designs. Plant-Derived Antimicrobial Peptides as Potential Antiviral agents are also under investigation. Studies have explored plant cyclotides that have demonstrated the ability to inhibit the growth of viruses. Similarly, in silico screening of potential plant peptides against the NS1, NS2, and NS3 targets of the dengue virus is revealing new avenues for peptide-based therapies.
The field is rapidly advancing, with ongoing research exploring various peptides and their mechanisms of action. For example, novel peptides derived from Hepatitis C virus NS5A have shown superior therapeutic efficacy against DENV, with Two peptides, 3a 3/20 and DS-05, being further evaluated for their potential in treating DHF/DSS induced by mouse-adapted DENV. This highlights the cross-disciplinary nature of peptide research, where insights from other viral infections can inform **d
Related Articles
Frequently Asked Questions
Here are the most common questions about .
Leave a Comment
Share your thoughts, feedback, or additional insights on this topic.
